AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Business Wire
New data finds AlphaVac F1885 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides significant improvement in right ventricular function and reduction in clot burden LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) were presented at The Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions hosted in Long Beach, California on May 3, 2024.Co-Principal Investigator William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™, gave a presentation titled “Evaluating the safety
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- AngioDynamics: A Story To Monitor [Seeking Alpha]Seeking Alpha
- AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions [Yahoo! Finance]Yahoo! Finance
- Insider Spends US$67k Buying More Shares In AngioDynamics [Yahoo! Finance]Yahoo! Finance
- A Leaner AngioDynamics Is A High-Risk Execution-Driven Story [Seeking Alpha]Seeking Alpha
- AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
ANGO
Earnings
- 4/4/24 - Miss
ANGO
Sec Filings
- 4/9/24 - Form 10-Q
- 4/8/24 - Form 4
- 4/4/24 - Form 8-K
- ANGO's page on the SEC website